Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin
Ponce Therapeutics, Inc. has launched its first R&D program targeting aging-associated skin disorders, focusing on eliminating p16-expressing cells. The company secured laboratory space in Houston, TX, and raised $1,500,000 through a Convertible Note financing led by Rapha Capital Management. This funding will support Ponce's transition into an operational entity. The executive team reunites expertise from the successful IPO of Bellicum Pharmaceuticals, aiming to leverage advancements in aging science for innovative anti-aging solutions.
- Secured $1,500,000 funding to support operational transition.
- First R&D program initiated focusing on aging-related skin disorders.
- Team includes experienced professionals behind a successful IPO from Bellicum Pharmaceuticals.
- None.
MIAMI, Feb. 8, 2021 /PRNewswire/ -- Ponce Therapeutics, Inc. ("Ponce"), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is highly expressed in both senescent cells and in in situ carcinoma (Bowen's Disease), which will be the focus of Ponce's efforts for first product approval.
Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment XIII, LLC ("RCI XIII") (an entity managed by Rapha Capital), led Ponce's recently closed Convertible Note financing. The
Rapha Capital is an investment management firm focused on making strategic investments in early stage, non-public biotechnology companies, through special purpose joint venture entities which it manages. Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon. After leaving practice, Dr. Slawin has been serving as a biotech consultant, investor, and founder, focusing on disruptive technologies in oncology, T cells and immunotherapy, and other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. ("Bellicum"), a publicly traded company listed on NASDAQ, leading Bellicum to a successful
Kevin Slawin, MD is the founder of Ponce, and will serve as the Chairman and CEO. David Spencer, PhD. is the founding Chief Technology Officer. Ponce Therapeutics, Inc. reunites the team that founded Bellicum Pharmaceuticals and took it public in 2014 with a
"The science of aging has continued to mature and can now provide a scientific basis for technologies to reverse the aging process in humans. Proof of concept data in animal models demonstrates that removal of senescent cells from organs improves their function and imbues them with a more youthful profile. Targeting p16-expressing cells for apoptotic elimination is one approach to removing senescent cells from the body and is also a valid approach to targeting Bowen's disease of the skin, which also expresses high levels of p16, profile," said Dr. Slawin. "I'm excited to begin work in the anti-aging space, which I believe will quickly rival oncology in both value and interest" he added. "Given our greater than two-decade animal model and clinical experience with regulated cell signaling and cell survival, along with recent advances in non-viral gene delivery platforms, we are now poised to leverage an increasingly detailed, mechanistic understanding of aging to arrest or even reverse it," added Dr. Spencer.
About Rapha Capital Management, LLC – Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on strategic investments in early stage, non-public biotechnology companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). He is co-Inventor of the FDA,-approved "prostate health index (phi)" test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America's Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.
About Ponce Therapeutics, Inc.
Ponce Therapeutics – "Anti-aging Technologies Based on Real Science and Developed by Real Scientists" - Ponce Therapeutics is leveraging the growing scientific knowledge surrounding the process of aging to develop its first state-of-the-art biotechnology platform to restore the youthful balance of aged or "senescent" and young cells in the skin, targeting the p16-expressing senescent cells for elimination. This provides a "reboot" of one's genetic program to turn the clock on one's skin back to its youthful exuberance. Targeting p16 will also potentially allow targeting of Bowen's disease as the regulatory pathway for approval. While initially focused on skin, Ponce is planning to develop a wide-ranging portfolio of anti-aging products based on the best science in the nascent anti-aging field. Ponce is headquartered in Miami, Florida with research facilities located in Houston, TX. For more information, visit www.poncethera.com or email info@poncethera.com.
For more information about Ponce Therapeutics, Inc., email info@poncethera.com or visit https://www.poncethera.com
For more information about Rapha Capital Management, email info@raphacapital.com or visit https://www.raphacap.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/ponce-therapeutics-inc-commences-first-r--d-program-in-anti-aging-products-for-skin-301221629.html
SOURCE Rapha Capital Management, LLC and Ponce Therapeutics, Inc.
FAQ
What is Ponce Therapeutics' focus in its new R&D program?
How much funding did Ponce Therapeutics secure recently?
Who led the financing for Ponce Therapeutics?
What is the significance of the p16 cell proliferation inhibitor for Ponce Therapeutics?
Who is the CEO of Ponce Therapeutics?
